Zhong Huijuan
Chinese pharmaceutical executive; founder, chair and CEO of Hansoh Pharmaceutical Group
| Zhong Huijuan
| |
|---|---|
| Born | 1961 (Forbes) Lianyungang, Jiangsu, China (Forbes) |
| Nationality | Chinese |
| Residence | Shanghai, China (Forbes) |
| Occupation | Pharmaceutical executive |
| Known for | Founder of Hansoh Pharmaceutical Group |
| Spouse(s) | Sun Piaoyang (Forbes) |
| Children | 1 – Sun Yuan (Forbes) |
| Education | BSc chemistry, Jiangsu Normal University (1982); EMBA, Nanjing University (2005) |
Zhong Huijuan (Chinese: 鍾慧娟; born 1961) is a Chinese pharmaceutical executive who founded Hansoh Pharmaceutical Group and is its chair and chief executive.[1][2] The company is based in Lianyungang and makes oncology, psychoactive, antidiabetic and other drugs. It listed on the Hong Kong Stock Exchange in 2019.[3] On 10 November 2026 the Forbes Real-Time Billionaires list ranked Zhong Huijuan 145th in the world, with an estimated net worth of US$18.9 billion; Forbes lists the source of wealth as pharmaceuticals.[3][4] In the annual World's Billionaires list published in 2026, Forbes had ranked Zhong Huijuan 151st, at US$18.7 billion.[5] Forbes reports that her husband, Sun Piaoyang, is also a billionaire and leads Jiangsu Hengrui Pharmaceuticals. Their daughter, Sun Yuan, is an executive director of Hansoh.[3][1]
Early life and education
Forbes gives her birthplace as Lianyungang in Jiangsu province.[3] According to Hansoh's 2024 annual report, she obtained an undergraduate degree in chemistry from Jiangsu Normal University (then Xuzhou Normal University) in July 1982 and an EMBA from Nanjing University in December 2005.[1]
Hansoh Pharmaceutical
Zhong became a director of Jiangsu Hansoh in September 1998 and a director of the listed company on 2 December 2015. The 2024 annual report describes her as the group's founder, chair of the board and chief executive. It credits her with about 30 years' experience in China's pharmaceutical industry, particularly in oncology and psychotropic drugs.[1] The listed parent company is incorporated in the Cayman Islands.[1] In 2024 the group reported revenue of about RMB 12.26 billion and ran research centres in Shanghai, Lianyungang and elsewhere.[1] Her total pay for 2024 was RMB 11.9 million.[1] International licensing. In December 2024 Hansoh granted a subsidiary of MSD an exclusive global licence for HS-10535, an experimental oral GLP-1 drug.[1] Forbes notes that Hansoh has licensed weight-loss treatments to companies including Merck in deals worth billions of dollars.[3] About a year before October 2026, Roche paid Hansoh US$80 million up front for the rights outside China to an antibody–drug conjugate (ADC), HS-20110.[6] On 19 October 2026 the two companies announced a second ADC collaboration. Hansoh is eligible for US$400 million up front, US$110 million on the first anniversary and possibly more than US$15 billion in milestones, and it keeps the rights in mainland China, Hong Kong, Macau and Taiwan.[7][6] Forbes also notes a 2022 partnership with the Global Health Drug Discovery Institute, which is backed by the Bill & Melinda Gates Foundation, to develop an oral COVID-19 treatment.[3]
Ownership and family
According to the 2024 annual report, Zhong and her daughter are each deemed interested in 3.9 billion shares, or 65.70% of Hansoh. The shares are held through Stellar Infinity, which is owned through a discretionary trust set up by Sun Yuan. Zhong holds consent rights over key matters of the trust.[1] In 2023 Forbes reported that the two owned more than three quarters of the company.[3] Sun Yuan holds a bachelor's degree in biomedical sciences from the University of Cambridge and worked as an analyst at Hony Capital before joining Hansoh in 2011.[1] In October 2026 trade press quoted her, as Eliza Sun, on the Roche deal.[6]
Wealth
Forbes lists her source of wealth as pharmaceuticals and classes her as self-made.[3]
Wealth history
Forbes has included this entry in its annual World's Billionaires list in 8 of the editions from 2001 to 2026 checked for this profile, starting with 2019. The table gives the rank and estimated net worth in each annual list.[5][3]
| Year | World's Billionaires rank | Net worth (US$ bn) |
|---|---|---|
| 2019 | 1425 | 1.6 |
| 2020 | 70 | 14.6 |
| 2021 | 89 | 19.7 |
| 2022 | 275 | 8.1 |
| 2023 | 290 | 7.6 |
| 2024 | 334 | 7.7 |
| 2025 | 257 | 10.5 |
| 2026 | 151 | 18.7 |
Honours and public roles
Hansoh's annual report states that she received a State Council Special Allowance in February 2013 and a State Science and Technology Award (second prize) in December 2014. It also describes her as co-president of the Hong Kong Jiangsu Enterprises Association.[1]
International and political links
This section uses the same ten headings for every profile in this series. Only specific, sourced actions are included; company-level and foundation-level actions are labelled as such. Where nothing was found, the entry reads "No documented involvement found in sources checked."
Israel (investments, operations, donations, contracts, statements)
No documented involvement found in sources checked.
Zionist or pro-Israel organisations and lobbying groups
No documented involvement found in sources checked.
Jewish communal charities
No documented involvement found in sources checked.
Gulf states
No documented involvement found in sources checked.
China
Zhong's business is based in mainland China. The company says she received a State Council Special Allowance in 2013 and a State Science and Technology Award in 2014, and that she is co-president of the Hong Kong Jiangsu Enterprises Association.[1]
Russia
No documented involvement found in sources checked.
India
No documented involvement found in sources checked.
Palestinian or Arab causes
No documented involvement found in sources checked.
Home government
See China. No other state or party position was found in the sources opened.[1]
Other international links
Company level: licensing deals with Roche of Switzerland and with MSD (Merck & Co.).[7][1]
See also
External links
Notes
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 Hansoh Pharmaceutical Group, 2024 Annual Report Hansoh Pharmaceutical Group Company Limited, April 2025, accessed 10 November 2026.
- ↑ Hansoh Pharmaceutical Group, Team management Hansoh Pharma, n.d., accessed 10 November 2026.
- ↑ 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 Forbes, Forbes profile record for Zhong Huijuan (Forbes data feed behind forbes.com/profile/zhong-huijuan/) Forbes, live record, read 10 November 2026, accessed 10 November 2026.
- ↑ Forbes, Forbes Real-Time Billionaires data feed Forbes, live; downloaded 10 November 2026 13:47 UTC, accessed 10 November 2026.
- ↑ 5.0 5.1 Forbes, Forbes World's Billionaires list data feed, annual editions 2001–2026 (one file per year at this path with the year substituted; all 26 files downloaded and read) Forbes, annual lists; downloaded 20 October 2026, accessed 10 November 2026.
- ↑ 6.0 6.1 6.2 James Waldron, Roche returns to China’s ADC powerhouse Hansoh for $15B biobucks pact Fierce Biotech, 19 October 2026, accessed 10 November 2026.
- ↑ 7.0 7.1 Hansoh Pharmaceutical Group, Hansoh Pharma announces strategic collaboration and license agreement with Roche to advance novel ADC portfolio Hansoh Pharma, 19 October 2026, accessed 10 November 2026.